An observational study in Lung Cancer, Non-Small Cell, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Tianjin Medical University Cancer Institute and Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital — 24 open to participants now, 25 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Tianjin Medical University Cancer Institute and Hospital.
Among the 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital, this one is one of 7 that started in 2026, is one of 2 observational ones, reaches primary completion later than 13 of the 24 other live ones, and was the 48th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →24 of the 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital are open now, in 1 country. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 35 · Phase 3 5 · Phase 4 1
First in 2009; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 52 across the 48 interventional studies, 275 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 499 studies on the registry; 298 are open to participants now.
6 of the studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06704620Phase 3Tianjin Medical University Cancer Institute and HospitalStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT06890182Tianjin Medical University Cancer Institute and HospitalFirmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | 2026-12 |
| NCT07561567Tianjin Medical University Cancer Institute and HospitalFeasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device | 2026-12-31 |
| NCT07330050Tianjin Medical University Cancer Institute and HospitalWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | 2026-12-31 |
| NCT07438600Tianjin Medical University Cancer Institute and HospitalStudy of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC | 2027-02-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to understand the safety and effectiveness of abdominal pressure devices in inhibiting respiratory movement in lung cancer patients. The main question it aims to answer is:
Did the abdominal pressure device reduce the respiratory movement of participants with lung cancer tumors?
Participants will:
Record how much they use abdominal pressure devices to suppress lung cancer tumor respiratory movement
This trial will enroll 50 patients with NSCLC scheduled to receive SBRT
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis is solitary peripheral lung cancer, and after comprehensive evaluation by the participating physicians based on the patient's clinical data, it is suitable for receiving SBRT treatment;
Exclusion Criteria:
Central or super central lung cancer patients who are intolerant or unwilling to undergo respiratory suppression and chest and abdominal compression fixation
CT/4DCT scan under breathing management
Device: Chest and abdominal compression · Device: breathing management
CT/4DCT scan under free breathing
Abdominal compression suppresses respiratory movement in patients
Apply pressure to the patient's abdomen to achieve respiratory movement inhibition
Tumor displacement range
Based on 4DCT for delineating tumor motion range and extracting radiomics features in patients with and without respiratory management
Time frame: Within 6 months after enrollment
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.
Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 7 months is below that.
Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Tianjin Medical University Cancer Institute and Hospital →